GLP-1, Kidney Disease and Dr Shuyao Zhang
New diabetes drugs could reduce kidney disease death risk
These drugs, called GLP1-RAs (short for glucagon-like peptide-1 receptor agonists), have been found to reduce hospital visits, slow kidney disease progression, and lower the risk of death for patients with both diabetes and kidney disease.
Medical Xpress on MSN9d
Yo-yo dieting may significantly increase kidney disease risk in people with type 1 diabetesBody-weight cycling (also known as yo-yo dieting) has been shown to significantly increase the risk of kidney disease in ...
Elevated serum fibroblast growth factor 23 levels at baseline are linked to a 29% increased risk for diabetic kidney disease, a recent observational study found.
Long-term weight stability is recommended to improve health outcomes in individuals with type 1 diabetes. Chronic kidney disease has been linked to yo-yo dieting (also known as body-weight ...
Hosted on MSN14d
Doctors Can Now Prescribe Ozempic to Reduce Kidney Disease Risks in Diabetes PatientsThe Food and Drug Administration (FDA) on Tuesday approved Ozempic (semaglutide) to reduce the risk of complications and death in adults with both type 2 diabetes and chronic kidney disease.
The US Food and Drug Administration on Tuesday approved Ozempic for adults with type 2 diabetes ... disease, and lower the risk of kidney disease. Ozempic is a glucagon-like peptide-1 ...
Body-weight cycling (also known as yo-yo dieting) has been shown to significantly increase the risk of kidney disease in people with type 1 diabetes, regardless of body mass index (BMI ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Weight cycling is a pattern in which people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback